- Home
- GTBP vs KLTO Comparison
GTBP vs KLTO Comparison
Compare GTBP & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- KLTO
- Stock Information
- Founded
- GTBP 1965
- KLTO 2019
- Country
- GTBP United States
- KLTO United States
- Employees
- GTBP N/A
- KLTO N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- GTBP Health Care
- KLTO
- Exchange
- GTBP Nasdaq
- KLTO NYSE
- Market Cap
- GTBP 5.5M
- KLTO 4.8M
- IPO Year
- GTBP N/A
- KLTO N/A
- Fundamental
- Price
- GTBP $2.23
- KLTO $0.22
- Analyst Decision
- GTBP Strong Buy
- KLTO
- Analyst Count
- GTBP 1
- KLTO 0
- Target Price
- GTBP $11.00
- KLTO N/A
- AVG Volume (30 Days)
- GTBP 17.4K
- KLTO 31.8M
- Earning Date
- GTBP 05-15-2025
- KLTO 05-15-2025
- Dividend Yield
- GTBP N/A
- KLTO N/A
- EPS Growth
- GTBP N/A
- KLTO N/A
- EPS
- GTBP N/A
- KLTO N/A
- Revenue
- GTBP N/A
- KLTO N/A
- Revenue This Year
- GTBP N/A
- KLTO N/A
- Revenue Next Year
- GTBP N/A
- KLTO N/A
- P/E Ratio
- GTBP N/A
- KLTO N/A
- Revenue Growth
- GTBP N/A
- KLTO N/A
- 52 Week Low
- GTBP $1.72
- KLTO $0.11
- 52 Week High
- GTBP $10.66
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- GTBP 46.01
- KLTO N/A
- Support Level
- GTBP $2.30
- KLTO N/A
- Resistance Level
- GTBP $2.37
- KLTO N/A
- Average True Range (ATR)
- GTBP 0.15
- KLTO 0.00
- MACD
- GTBP -0.01
- KLTO 0.00
- Stochastic Oscillator
- GTBP 14.55
- KLTO 0.00
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.